- Home
- ANTX vs BNR Comparison
ANTX vs BNR Comparison
Compare ANTX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- BNR
- Stock Information
- Founded
- ANTX 2017
- BNR 2014
- Country
- ANTX United States
- BNR China
- Employees
- ANTX N/A
- BNR N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- ANTX Health Care
- BNR Health Care
- Exchange
- ANTX Nasdaq
- BNR Nasdaq
- Market Cap
- ANTX 33.2M
- BNR 29.1M
- IPO Year
- ANTX 2022
- BNR 2020
- Fundamental
- Price
- ANTX $1.07
- BNR $3.86
- Analyst Decision
- ANTX Buy
- BNR
- Analyst Count
- ANTX 2
- BNR 0
- Target Price
- ANTX $2.00
- BNR N/A
- AVG Volume (30 Days)
- ANTX 287.0K
- BNR 35.7K
- Earning Date
- ANTX 08-12-2025
- BNR 08-21-2025
- Dividend Yield
- ANTX N/A
- BNR N/A
- EPS Growth
- ANTX N/A
- BNR N/A
- EPS
- ANTX N/A
- BNR N/A
- Revenue
- ANTX N/A
- BNR $72,112,038.00
- Revenue This Year
- ANTX N/A
- BNR $136.32
- Revenue Next Year
- ANTX N/A
- BNR N/A
- P/E Ratio
- ANTX N/A
- BNR N/A
- Revenue Growth
- ANTX N/A
- BNR 0.53
- 52 Week Low
- ANTX $0.87
- BNR $2.18
- 52 Week High
- ANTX $3.07
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- ANTX 45.19
- BNR 62.38
- Support Level
- ANTX $1.07
- BNR $3.06
- Resistance Level
- ANTX $1.11
- BNR $3.50
- Average True Range (ATR)
- ANTX 0.04
- BNR 0.23
- MACD
- ANTX 0.00
- BNR 0.03
- Stochastic Oscillator
- ANTX 15.04
- BNR 87.26
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.